Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 535mg equivalent to cefaclor 500 mg (plus 2% overage.) - capsule - 500 mg - active: cefaclor monohydrate 535mg equivalent to cefaclor 500 mg (plus 2% overage.) excipient: brilliant blue fcf carmoisine colloidal silicon dioxide croscarmellose sodium gelatin   iron oxide black magnesium stearate methyl hydroxybenzoate   ponceau 4r pregelatinised maize starch propyl hydroxybenzoate   titanium dioxide  

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 27.8 mg/ml equivalent to cefaclor 25 mg/ml;   - granules for oral suspension - 125 mg/5ml - active: cefaclor monohydrate 27.8 mg/ml equivalent to cefaclor 25 mg/ml   excipient: allura red ac citric acid colloidal silicon dioxide simeticone sodium benzoate sodium citrate dihydrate strawberry flavour 052311 ap0551 sucrose xanthan gum - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated micro-organisms: lower respiratory infections, including pneumonia caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains), and s. pyogenes (group a beta- haemolytic streptococci), m.catarrhalis, acute bronchitis, and acute exacerbations of chronic bronchitis. upper respiratory infections, including pharyngitis and tonsillitis caused by s. pyogenes (group a beta-haemolytic streptococci) and m. catarrhalis. otitis media caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains) staphylococci, and s. pyogenes (group a beta-haemolytic streptococci), and m. catarrhalis. skin and soft-tissue infections caused by staphylococcus aureus (including ?-lactamase producing strains), s. pyogenes (group a beta-haemolytic streptococci) and staphylococcus epidermidis (including ?-lactamase produc

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 55.6 mg/ml equivalent to cefaclor 50 mg/ml - granules for oral suspension - 250 mg/5ml - active: cefaclor monohydrate 55.6 mg/ml equivalent to cefaclor 50 mg/ml excipient: allura red ac citric acid colloidal silicon dioxide simeticone sodium benzoate sodium citrate dihydrate strawberry flavour 052311 ap0551 sucrose xanthan gum

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 405.27mg equivalent to cefaclor 375 mg - modified release tablet - 375 mg - active: cefaclor monohydrate 405.27mg equivalent to cefaclor 375 mg excipient: colloidal silicon dioxide hyprolose hypromellose lactose monohydrate magnesium stearate opacode opadry blue purified talc

США - англійська - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 400 mg - gabapentin capsules, usp are indicated for the management of postherpetic neuralgia in adults. gabapentin capsules, usp are indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. gabapentin capsules, usp are also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 to 12 years. gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. gabapentin is not a scheduled drug. gabapentin does not exhibit affinity for benzodiazepine, opiate (mu, delta or kappa), or cannabinoid 1 receptor sites. a small number of postmarketing cases report gabapentin misuse and abuse. these individuals were taking higher than recommended doses of gabapentin for unapproved uses. most of the individuals described in these reports had a history of poly-substance abuse or used gabapentin to relieve symptoms of withdrawal from other substan

США - англійська - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - tablet - 7.5 mg - carefully consider the potential benefits and risks of meloxicam and other treatment options before deciding to use meloxicam. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). meloxicam is indicated for relief of the signs and symptoms of osteoarthritis. meloxicam is contraindicated in patients with known hypersensitivity to meloxicam. meloxicam should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings , anaphylactoid reactions , and precautions , pre-existing asthma ). meloxicam is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (see warnings ).

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ranbaxy (malaysia) sdn. bhd. - rosuvastatin calcium -

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ranbaxy (malaysia) sdn. bhd. - rosuvastatin calcium -

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ranbaxy (malaysia) sdn. bhd. - montelukast sodium -

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ranbaxy (malaysia) sdn. bhd. - enalapril maleate -